Exploring 3 High Growth Tech Stocks in Europe

Posted by Admin February 28, 2025 Tech

Amid cautious optimism in Europe, the pan-European STOXX Europe 600 Index recently edged higher by 0.26% as investors weighed developments in U.S. trade policy and efforts to resolve the Russia-Ukraine conflict, while eurozone business activity showed signs of stagnation despite remaining in expansionary territory. In such a dynamic market environment, identifying high-growth tech stocks often involves looking for companies that demonstrate strong innovation capabilities and resilience to economic shifts, which are crucial factors given the current geopolitical and economic landscape.

Name	Revenue Growth	Earnings Growth	Growth Rating
Elicera Therapeutics	57.37%	97.24%	★★★★★★
CD Projekt	27.11%	39.37%	★★★★★★
Yubico	21.27%	26.82%	★★★★★★
Truecaller	20.03%	24.78%	★★★★★★
XTPL	97.45%	117.95%	★★★★★★
Ascelia Pharma	46.09%	66.93%	★★★★★★
Pharma Mar	23.77%	45.40%	★★★★★★
Skolon	29.71%	91.18%	★★★★★★
Elliptic Laboratories	61.01%	121.13%	★★★★★★
Initiator Pharma	73.95%	31.67%	★★★★★★

Click here to see the full list of 246 stocks from our European High Growth Tech and AI Stocks screener.

Let’s uncover some gems from our specialized screener.

Simply Wall St Growth Rating: ★★★★★☆

Overview: Izertis, S.A. is a technological consultancy firm operating in Spain, Portugal, and Mexico with a market capitalization of €255.69 million.

Operations: The company, alongside its subsidiaries, generates revenue primarily from providing technological consultancy services in Spain, Portugal, and Mexico. The Technologies and Information (IT) segment accounts for €124.33 million in revenue.

Izertis, a dynamic player in the European tech scene, showcases robust financial health with an impressive annual revenue growth rate of 22.3%, significantly outpacing the broader Spanish market’s average of 5.2%. This growth is complemented by a striking earnings increase, projected at 40.9% annually, dwarfing the domestic market’s expectations of just 7.7%. Despite these strong performance indicators, it’s crucial to note that Izertis’ earnings growth last year did not surpass the IT industry average of 9.9%, highlighting competitive pressures. Moreover, concerns arise as interest payments are not well covered by earnings, signaling potential financial strain. However, with high-quality past earnings and a forecasted Return on Equity at 14.1%, Izertis remains poised for future endeavors albeit with caution due to its mixed financial coverage metrics.

BME:IZER Revenue and Expenses Breakdown as at Feb 2025

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Promotora de Informaciones, S.A. operates in the media industry both in Spain and internationally, with a market cap of €379.23 million.

Operations: The company, along with its subsidiaries, is involved in media exploitation across Spain and international markets.

Promotora de Informaciones (PRS) is navigating the competitive European tech landscape with mixed results. Despite a revenue growth of 7.4% per year, which surpasses the Spanish market average of 5.2%, PRS’s profitability is on a slower trajectory, with an anticipated shift from losses to profits within three years. The company’s R&D investment underscores its commitment to innovation, crucial in maintaining relevance amidst rapid technological advancements; however, details on exact figures were not disclosed. Recent earnings reports indicate a significant reduction in net loss from EUR 32.51 million last year to EUR 11.57 million this year, reflecting stringent cost control and operational improvements. While these developments are promising, PRS’s financial health requires careful monitoring due to its past performance volatility and ongoing market pressures.

BME:PRS Earnings and Revenue Growth as at Feb 2025

Simply Wall St Growth Rating: ★★★★☆☆

Overview: argenx SE is a biotechnology company focused on developing therapies for autoimmune diseases across several regions including the United States, Japan, Europe, the Middle East, Africa, and China, with a market cap of €37.15 billion.

Operations: The biotechnology firm specializes in creating therapies for autoimmune diseases, operating across multiple regions such as the United States, Japan, and Europe. It holds a significant market presence with a capitalization of approximately €37.15 billion.

Argenx SE showcases a robust trajectory in the high-growth tech sector, particularly with its recent leap from a net loss of $295.05 million to a net income of $833.04 million within one year, underscoring significant operational efficiency and market impact. The company’s strategic focus on innovative treatments like VYVDURA, which has seen approval for new indications, supports sustained growth—evidenced by an impressive revenue surge from $1.27 billion to over $2.25 billion annually. This performance is bolstered by argenx’s commitment to R&D, crucial for maintaining competitive advantage in the fast-evolving biotech landscape.

ENXTBR:ARGX Revenue and Expenses Breakdown as at Feb 2025

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include BME:IZER BME:PRS and ENXTBR:ARGX.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com